BioCentury
ARTICLE | Clinical News

Viracta starts Phase Ib/II of VRx-3996 for Epstein-Barr virus-positive lymphomas

April 13, 2018 3:22 PM UTC

Viracta Therapeutics Inc. (San Diego, Calif.) began the Phase Ib/II VT3996-201 trial of VRx-3996 (chr-3996) in combination with valganciclovir to treat Epstein-Barr virus-positive lymphomas.

The open-label, U.S. trial is enrolling up to 40 patients. The trial’s primary endpoints are safety and overall response rate (ORR). Secondary responses include time to response, duration of response, progression-free survival (PFS) and pharmacokinetics...

BCIQ Company Profiles

Viracta Therapeutics Inc.

BCIQ Target Profiles

Histone deacetylase (HDAC)